Please assess the completion status of the following clinical trial:

Trial Title: Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* CABG candidate~* At least 4 akinetic segments~* First anterior heart attack within in 10 days to 3 month.~* St elevation MI defined by: Post Acute MI LVEF less than 45% as assessed by echocardiography.~* The target lesion had to be located in the left anterior descending (LAD) section.~Exclusion Criteria:~* History of prior anterior myocardial infarction:~* History of prior CABG~* Poor echocardiography window.~* Active infection or history of recurrent infection or positive test for syphilis (RPR), hepatitis B and C (HBSAg/ Anti HBc Anti - Hcv) HIV and HTLV-l~* Documental terminal illness or malignancy.~* Previous bone marrow transplant~* Autoimmune disease (e. g Lupus, Multiple sclerosis)~* Any contraindication for bone - marrow aspiration.~* Positive pregnancy test (in women with child bearing potential)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MNC implantation (Type: EXPERIMENTAL): Implantation of BM derived MNC
- AC 133 implantation (Type: EXPERIMENTAL): Implantation of BM derived AC 133
- Control (Type: PLACEBO_COMPARATOR): Injection of cell carrier

Based on this trial design, predict the completion outcome and termination type (if applicable).